Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy

Contrast-induced Nephropathy Clinical Trial

Official title: Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy

Status Recruiting

Clinical Trial Summary

The investigators planned to research the effect of vitamin D supplementation on the incidence of contrast-induced nephropathy in patients undergoing coronary angiography.

Clinical Trial Description

Vitamin D is primarily generated in the skin, in response to direct absorption of ultraviolet B radiation. Vitamin D can also be obtained through fortified foods and oral supplements. Contrast-induced nephropathy (CIN) is a generally reversible form of acute kidney injury that occurs mostly within 2-3 days of exposure to contrast medium (CM). The estimated incidence of CIN ranges from 2%-50%, and coronary angiography (CAG) or percutaneous coronary intervention (PCI), or both, are associated with CIN in about half of cases. Recently low vitamin D status has been shown to be associated with increased risk of CIN. However, its effects on CIN patients remain unclear. The investigators planned to determine the efficacy of vitamin D on the incidence of contrast-induced nephropathy in patients undergoing coronary angiography. This study may shed light as to whether oral vitamin D supplementation can be an adjunct therapy in CIN patients. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Contrast-induced Nephropathy
• Kidney Diseases

• NCT number: NCT02489240
• Study type: Interventional
• Source: Chinese PLA General Hospital
• Contact: Yang Shi, M.D.
• Phone: +8610-66876231
• Email: ggyyong@sina.com
• Status: Recruiting
• Phase: N/A
• Start date: July 2015
• Completion date: July 2017